REPORTS

Let’s Pullulate and Expand Your Business

Recombinant Protein Drug Market - Global Professional Analysis and Forecast to 2026

Oct 25, 2019  |  154 PAGES  |  REPORT CODE: CMM223848
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Recombinant Protein Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.0% during the forecast period.

This report presents the market size and development trends by detailing the Recombinant Protein Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Recombinant Protein Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Recombinant Protein Drug industry and will help you to build a panoramic view of the industrial development.

Recombinant Protein Drug Market, By Type:

  • Recombinant Insulin

  • Recombinant Human Interferon (rhIFN)

  • Recombinant Human Erythropoietin (rhEPO)

  • Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)

  • Recombinant Human Growth Hormone (rhGH)

  • Recombinant Human Follicle-stimulating Hormone (rhFSH)

  • Others

Recombinant Protein Drug Market, By Application:

  • Hospital use

  • Clinic use

  • Household

Some of the leading players are as follows:

  • Merck Serono

  • Changchun High & New Technology Industry

  • Livzon Pharmaceutical

  • Roche

  • Shenzhen Neptunus Interlong Bio-Technique

  • Eli Lilly

  • Kyowa Hakko Kirin

  • Heng Rui

  • GenSci

  • Ortho Biotech

  • NCPC

  • Abcam

  • SL PHARM

  • Pharmingen

  • Sanofi

  • Amgen

  • Novo Nordisk

  • Anhui Anke Biotechnology

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Recombinant Protein Drug Market: Technology Type Analysis

  • 4.1 Recombinant Protein Drug Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Recombinant Protein Drug Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Recombinant Insulin

    • 4.3.2 Recombinant Human Interferon (rhIFN)

    • 4.3.3 Recombinant Human Erythropoietin (rhEPO)

    • 4.3.4 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)

    • 4.3.5 Recombinant Human Growth Hormone (rhGH)

    • 4.3.6 Recombinant Human Follicle-stimulating Hormone (rhFSH)

    • 4.3.7 Others

5 Recombinant Protein Drug Market: Product Analysis

  • 5.1 Recombinant Protein Drug Product Market Share Analysis, 2018 & 2026

  • 5.2 Recombinant Protein Drug Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Recombinant Protein Drug Market: Application Analysis

  • 6.1 Recombinant Protein Drug Application Market Share Analysis, 2018 & 2026

  • 6.2 Recombinant Protein Drug Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospital use

    • 6.3.2 Clinic use

    • 6.3.3 Household

7 Recombinant Protein Drug Market: Regional Analysis

  • 7.1 Recombinant Protein Drug Regional Market Share Analysis, 2018 & 2026

  • 7.2 Recombinant Protein Drug Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Merck Serono

    • 9.1.1 Merck Serono Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Changchun High & New Technology Industry

    • 9.2.1 Changchun High & New Technology Industry Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Livzon Pharmaceutical

    • 9.3.1 Livzon Pharmaceutical Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Roche

    • 9.4.1 Roche Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Shenzhen Neptunus Interlong Bio-Technique

    • 9.5.1 Shenzhen Neptunus Interlong Bio-Technique Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Eli Lilly

    • 9.6.1 Eli Lilly Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Kyowa Hakko Kirin

    • 9.7.1 Kyowa Hakko Kirin Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Heng Rui

    • 9.8.1 Heng Rui Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 GenSci

    • 9.9.1 GenSci Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Ortho Biotech

    • 9.10.1 Ortho Biotech Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 NCPC

    • 9.11.1 NCPC Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Abcam

    • 9.12.1 Abcam Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 SL PHARM

    • 9.13.1 SL PHARM Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Pharmingen

    • 9.14.1 Pharmingen Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Sanofi

    • 9.15.1 Sanofi Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Amgen

    • 9.16.1 Amgen Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Novo Nordisk

    • 9.17.1 Novo Nordisk Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Anhui Anke Biotechnology

    • 9.18.1 Anhui Anke Biotechnology Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

 

The List of Tables and Figures (Totals 113 Figures and 164 Tables)

  • Figure Recombinant Insulin Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Recombinant Human Interferon (rhIFN) Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Recombinant Human Erythropoietin (rhEPO) Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF) Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Recombinant Human Growth Hormone (rhGH) Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Recombinant Human Follicle-stimulating Hormone (rhFSH) Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Others Recombinant Protein Drug market, 2015 - 2026 (USD Million)

  • Figure Hospital use market, 2015 - 2026 (USD Million)

  • Figure Clinic use market, 2015 - 2026 (USD Million)

  • Figure Household market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Recombinant Protein Drug market, by country, 2015 - 2026 (USD Million)

  • Table North America Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table North America Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table North America Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Canada Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Canada Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Europe Recombinant Protein Drug market, by country, 2015 - 2026 (USD Million)

  • Table Europe Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Europe Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Europe Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Germany Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Germany Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table France Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table France Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Italy Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Italy Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Spain Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Spain Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Recombinant Protein Drug market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table China Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table China Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Japan Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Japan Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table India Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table India Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Recombinant Protein Drug market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table MEA Recombinant Protein Drug market, by country, 2015 - 2026 (USD Million)

  • Table MEA Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table MEA Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table MEA Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Recombinant Protein Drug market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Recombinant Protein Drug market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Recombinant Protein Drug market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Merck Serono Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Changchun High & New Technology Industry Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Livzon Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Shenzhen Neptunus Interlong Bio-Technique Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Kyowa Hakko Kirin Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Heng Rui Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GenSci Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ortho Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table NCPC Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abcam Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table SL PHARM Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pharmingen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Anhui Anke Biotechnology Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top